3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine | 1595291-53-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine
• 英文别名: 3-((3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine；3-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl]pyridine
• CAS: 1595291-53-4
• 化学式: C₁₈H₂₂BNO₃
• 分子量: 311.189
• InChiKey: IWCPUASIKAPYEW-UHFFFAOYSA-N

物化性质

• 沸点：
  454.9±30.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.96
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine 在 tris-(dibenzylideneacetone)dipalladium(0) 、 四(三苯基膦)钯 、 sodium carbonate 、 potassium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 、 水 、 叔丁醇 为溶剂， 反应 17.0h， 生成 N-phenyl-4-(3-(pyridin-3-ylmethoxy)phenyl)-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-2-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted 2-anilino-7H-pyrrolopyrimidines as PDK1 inhibitors

  摘要：

  An efficient and scalable route for a series of novel substituted 2-anilino-7H-pyrrolopyrimidine compounds as potential inhibitors of PDK1, an important regulator of the PI3K/Akt pathway that is dysregulated in many cancers, was developed and is described. The synthetic strategy was designed around Suzuki and Buchwald-Hartwig cross-couplings of a boronate fragment and various customised anilines sequentially with 2,4-dichloro-7-tosyl-7H-pyrrolopyrimidine. All fragments were constructed separately and cross-coupled to provide access to a range of novel compounds. Biological evaluation of these was undertaken, with modest inhibition observed. Crown Copyright (C) 2014 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.05.033
• 作为产物：
  描述：

  3-氯甲基吡啶盐酸盐 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 caesium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 64.0h， 生成 3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl)pyridine
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted 2-anilino-7H-pyrrolopyrimidines as PDK1 inhibitors

  摘要：

  An efficient and scalable route for a series of novel substituted 2-anilino-7H-pyrrolopyrimidine compounds as potential inhibitors of PDK1, an important regulator of the PI3K/Akt pathway that is dysregulated in many cancers, was developed and is described. The synthetic strategy was designed around Suzuki and Buchwald-Hartwig cross-couplings of a boronate fragment and various customised anilines sequentially with 2,4-dichloro-7-tosyl-7H-pyrrolopyrimidine. All fragments were constructed separately and cross-coupled to provide access to a range of novel compounds. Biological evaluation of these was undertaken, with modest inhibition observed. Crown Copyright (C) 2014 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.05.033

文献信息

• [EN] TREATMENT OF GVHD<br/>[FR] TRAITEMENT DE LA RÉACTION DU GREFFON CONTRE L'HÔTE
  申请人：KADMON CORP LLC

  公开号：WO2015157556A1

  公开（公告）日：2015-10-15

  The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD ( cGVHD) using compounds having the formulae l-XXV, as set forth herein.

  这项发明涉及使用抑制ROCK2的化合物治疗移植物抗宿主病（GVHD）。在首选方面，本发明提供了治疗GVHD的方法，包括慢性GVHD（cGVHD），使用具有以下公式的化合物l-XXV。
• TREATMENT OF OCULAR DISORDERS
  申请人：KADMON CORPORATION, LLC

  公开号：US20150238601A1

  公开（公告）日：2015-08-27

  The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.

  本发明提供了治疗眼部疾病的方法，包括具有血管生成成分的眼部疾病。在某些实施例中，治疗包括给予ROCK2抑制剂和血管生成抑制剂。在某些实施例中，ROCK2抑制剂是ROCK2选择性的。在某些实施例中，血管生成抑制剂是VEGF拮抗剂，例如VEGFR2抗体。
• RHO KINASE INHIBITORS
  申请人：KADMON CORPORATION

  公开号：US20150252025A1

  公开（公告）日：2015-09-10

  The invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.

  本发明涉及ROCK1和/或ROCK2的抑制剂。还提供了通过抑制ROCK1和/或ROCK2治疗涉及疾病和障碍的方法。
• [EN] TREATMENT OF OCULAR DISORDERS<br/>[FR] TRAITEMENT DE TROUBLES OCULAIRES
  申请人：KADMON CORP LLC

  公开号：WO2014055999A3

  公开（公告）日：2014-05-30